US › Healthcare

Standard Biotools Inc (LAB)

US · Healthcare · Medical Devices

$0.64+2.83%

Last close · 2026-11-06

Latest quarter · ended 2026-09-30

Revenue

$19.4M

Revenue YoY

-0.9%

Net profit

$13.5M

EPS

$-0.06

EPS estimate

$-0.01

Net margin

69.6%

EPS came in at -0.06 against a street estimate of -0.01 — a miss of 500.0%.

Key statistics

Market cap

$243.2M

Forward P/E

0.0

P/B

0.45

Book value

$1.41

EPS (TTM)

$-0.09

52-week high

$1.72

52-week low

$0.59

50-day MA

$0.68

200-day MA

$0.90

Beta

1.51

Analyst view

Analysts rate Standard Biotools Inc a hold (0 buy, 1 hold, 0 sell out of 1) with an average price target of $1.35.

Shareholding

Insiders

1.82%

Institutions

75.20%

Largest institutional holders

Fund	Stake
Casdin Capital, LLC	22.68%
Viking Global Investors LP	14.98%
Mak Capital One LLC	7.36%
Long Focus Capital Management, LLC	6.00%
Vanguard Capital Management, LLC	3.13%
BlackRock Inc	2.11%
Hollow Brook Wealth Management, LLC	1.33%
Neuberger Berman Group LLC	1.27%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Standard Biotools Inc — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-11-07.